Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial

Trial Profile

Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial

Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Sodium nitrite (Primary)
  • Indications Kidney disorders
  • Focus Pharmacodynamics
  • Acronyms NICE
  • Most Recent Events

    • 11 Aug 2017 Status changed from recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 21 Mar 2016 Protocol amended as dose of Isoquercetin changed from 250 mg to 225 mg, Vitamin C has been removed from treatments and dosage form changed from sustained to immediate release, as reported by record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top